Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Three-arm Randomized Phase II Study of Dostarlimab Alone or with Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV07/ ENGOT-ov80 Study)

Next Previous
Trial Profile

A Three-arm Randomized Phase II Study of Dostarlimab Alone or with Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV07/ ENGOT-ov80 Study)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Dostarlimab (Primary) ; Doxorubicin; Gemcitabine; Paclitaxel
  • Indications Carcinoma; Cervical cancer; Endometrial cancer; Ovarian cancer; Vulvovaginal cancer
  • Focus Therapeutic Use
  • Acronyms APGOT-ov7; DOVE; ENGOT-ov80 Study

Most Recent Events

  • 18 Jun 2024 Status changed from not yet recruiting to recruiting.
  • 04 Jun 2024 Trial design from this study were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
  • 02 Jan 2024 Planned initiation date changed from 25 Sep 2023 to 22 Jan 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top